Is Hormone Replacement Therapy for Menopause Safe? New Research on the Safety of Menopause Treatment
For more than two decades, hormone replacement therapy has carried a reputation shaped more by fear than by context. If you’re in perimenopause or menopause now, someone may have told you HRT is dangerous. That fear didn’t come from nowhere, but it wasn’t the whole story on menopause treatment.
In February 2026, the FDA approved a sweeping change to hormone therapy labeling, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had remained on these products since the early 2000s. The update represents one of the most significant shifts in menopause treatment guidance in a generation.
Why HRT Got Its Scary Reputation
In 2002, the Women’s Health Initiative, a large federal study, released early findings linking hormone therapy to breast cancer, heart disease, stroke, and blood clots. Use dropped by nearly half overnight, and a boxed warning stayed on these medications for over two decades.
What many people weren’t told: the women studied were, on average, in their early sixties, with some participants as old as 79, placing many more than a decade beyond the typical onset of menopause. They were also given a formulation that is less commonly prescribed today.
Because many of these women had gone years without the protective effects of naturally occurring hormones, some may have already had underlying cardiovascular changes before starting therapy, which influenced the results.
Since then, researchers revisiting the data have found a different picture for women beginning hormone replacement therapy for menopause closer to the transition.
What Changed: The Research Behind the FDA's Decision
The 2026 update followed a comprehensive review, a 2025 expert panel, and public comment. According to the FDA update on menopausal hormone therapy labeling changes, the revised labeling is intended to better reflect current scientific evidence and support more informed, individualized treatment decisions made by women and their healthcare providers.
Key findings included:
• Women beginning hormone replacement therapy as a treatment for menopause within ten years of menopause onset showed reduced all-cause mortality and fracture risk.
• They also demonstrated a more favorable cardiovascular profile, including a lower risk of coronary heart disease, the leading cause of death among women in the United States.
• Emerging research suggests potential cognitive benefits, though this continues to be researched.
• A pooled analysis of 30 trials involving more than 26,000 women found no link that hormone therapy causes an increased risk of cancer mortality.
It’s worth being precise about what the FDA did and didn’t do.
The FDA:
• Removed the boxed warnings (often referred to as black box warnings) related to cardiovascular disease, breast cancer, and probable dementia.
• Retained the warning for endometrial cancer with systemic estrogen-alone therapy in women with a uterus.
• This is why pairing estrogen with progesterone remains standard for women who have a uterus. Progesterone helps balance estrogen’s effects on the uterine lining and reduces the risk of endometrial overgrowth.
The Menopause Society has also emphasized that hormone therapy decisions should be individualized based on a woman’s health history, symptoms, age, timing, formulation, and personal risk factors.
The FDA update did not declare HRT safe for everyone. Menopause treatment is not one-size-fits-all, and the balance between benefits and risks requires a personalized approach.
Why Timing Still Matters in Menopause Treatment
While timing can influence the benefits and risks associated with hormone therapy, menopause treatment decisions cannot be based on age or years since menopause alone.
Some women who are more than ten years past menopause may still be appropriate candidates for hormone therapy after a careful evaluation of their health history, symptoms, risk factors, and individual goals. These decisions require a personalized assessment that weighs potential benefits against individual risks.
Menopause care is not about applying a single rule to every woman. It involves understanding the full picture, including cardiovascular health, bone health, symptom severity, family history, lifestyle factors, and personal preferences.
This raises an important question: what if you’re already over 60 or more than 10 years past menopause? Is hormone therapy still an option?
Can You Start Hormone Replacement Therapy After Age 60?
For many years, women were told that menopause treatment with hormone replacement therapy should only be started before age 60 or within 10 years of menopause. That recommendation was largely influenced by the early findings of the National Institutes of Health (NIH) Women’s Health Initiative (WHI), which reported higher rates of cardiovascular events and blood clots in some women receiving hormone therapy. While those findings changed clinical practice, researchers now recognize that they reflected outcomes in an older population using hormone formulations that are less commonly prescribed today.
As additional evidence has emerged, the understanding of hormone therapy has evolved. More recent research suggests that the decision to begin hormone replacement therapy after age 60 should be individualized rather than based on age alone. According to The Menopause Society, menopause treatment should be guided by a woman’s overall health, symptom severity, personal goals, and risk factors instead of relying on a fixed age cutoff.
For carefully selected women, systemic hormone therapy may still provide meaningful benefits, particularly when hot flashes, night sweats, sleep disruption, or other menopausal symptoms continue to affect quality of life. Depending on an individual’s health profile, treatment may also help support bone health, muscle mass, metabolic health, cognitive function, and sexual health. The FDA’s updated guidance on menopausal hormone therapy also emphasizes individualized decision-making based on current scientific evidence and discussions between women and their healthcare providers.
Although the absolute risks of conditions such as stroke, coronary artery disease, venous thromboembolism, and dementia generally increase with age, those risks vary considerably from one woman to another. Both the FDA and the Menopause Society recommend evaluating personal and family medical history, cardiovascular health, the type of hormone prescribed, and the route of administration before making decisions about menopause treatment.
The takeaway is simple: age alone should not automatically determine whether hormone replacement therapy is appropriate. While the strongest evidence for a favorable benefit-risk profile remains in women who begin treatment closer to menopause, growing research supports a personalized approach to menopause treatment for some women over 60 when evaluated by a clinician experienced in menopause care.
The takeaway is simple:
Age alone should not automatically determine whether hormone replacement therapy is appropriate. While the strongest evidence for a favorable benefit-risk profile remains in women who begin treatment before age 60 or within 10 years of menopause, recent clinical research continues to support a more individualized approach for carefully selected women beyond these traditional thresholds. Treatment decisions should be based on a comprehensive evaluation of a woman’s health, symptoms, goals, and personal risk factors rather than an arbitrary age cutoff.
Delivery Method Matters, Too
How hormones are delivered can influence their risk profile and how they affect the body.
• Transdermal estrogen (patches, gels, creams): Topical estrogen delivery bypasses initial liver processing and is not associated with an increased risk of blood clots or stroke above a woman’s personal baseline risk. Research has shown it may have a more favorable risk profile compared with oral estrogen.
• Women with a uterus: Women with a uterus typically need progesterone alongside estrogen to balance estrogen’s effects on the uterine lining and reduce the risk of endometrial overgrowth. Many women also choose progesterone for additional benefits related to sleep, calming effects, and bone health.
• After hysterectomy: Estrogen-alone therapy remains an option for many women who have had a hysterectomy, although some may still choose progesterone for additional benefits beyond uterine protection.
A Personalized Approach
This is genuinely good news, but not a green light for every woman, it was never meant to be. The FDA frames the update as giving women and providers better information for individualized decisions, not a blanket recommendation.
This is where naturopathic medicine adds something conventional care alone often can’t. In my practice, a conversation about menopause treatment never starts with a prescription pad. It starts with understanding your complete health picture, including your medical history, current symptoms, lab work, lifestyle, and long-term health goals.
When I work with women who are more than 10 years beyond menopause or over age 60, the decision about hormone therapy is rarely made in a single visit. Instead, we take the time to understand your individual balance of benefits and risks. That includes reviewing your cardiovascular health, metabolic health, bone health, endocrine function, medications, family history, and the severity of your symptoms before deciding whether hormone therapy is the right option.
Depending on your health history, I may recommend additional testing to better understand your cardiovascular, metabolic, endocrine, and bone health before initiating treatment. These evaluations help us make decisions based on your current health rather than relying on age alone. While many women are appropriate candidates for hormone therapy, others achieve excellent results through a personalized plan centered on nutrition, herbal medicine, targeted supplementation, and lifestyle strategies.
Every treatment plan is different because every woman is different. Some women benefit from bioidentical hormone therapy alongside nutrition and lifestyle support, while others experience meaningful improvements without hormones. The goal is never to fit you into a predetermined treatment pathway. It’s to identify the approach that best supports your symptoms, protects your long-term health, and aligns with your personal goals.
Menopause affects far more than hormone levels alone. It can influence bone density, cardiovascular health, mood, sleep, metabolism, sexual health, and overall quality of life. That’s why I focus on supporting the whole person rather than treating isolated symptoms.
Supporting bone health is an essential part of menopause treatment, which is why personalized osteoporosis treatment and prevention is often included in a comprehensive care plan, particularly for women at higher risk of fractures.
Conclusion
The conversation around hormone replacement therapy has evolved significantly over the past two decades, as newer research has provided a more complete understanding of who benefits most and when. The fear that kept women away from effective treatment was based on incomplete data, and only now is the fuller picture catching up. If you’ve wondered whether menopause treatment could help you, this is a good moment to ask again, ideally with someone who looks at your whole health history rather than a single headline from 2002.
-Dr. Korza
If you’re wondering whether hormone therapy is right for you, or you’ve been told you’re not a candidate because of your age or the number of years since menopause, you don’t have to navigate that decision alone. Schedule your consultation to discuss your symptoms, review your health history, and create a personalized menopause treatment plan that’s right for you.
